VWA
TRIL

V Wealth Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

V Wealth Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100
Closed – – 767
2017
Q2 		$0 Buy
+100
New +$553 ﹤0.01% 836

Other funds holding TRIL

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

V Wealth Advisors's TRIL Position: Q3 2017 in Review

V Wealth Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2017, closing a stake of 100 shares.

V Wealth Advisors first reported a position in TRIL in Q2 2017 and held it in 1 quarter. The position peaked at $0 in Q2 2017. 20 funds tracked by Wall St. Rank hold TRIL as of Q3 2017.

  • V Wealth Advisors reported no remaining Trillium Therapeutics Inc. position as of Q3 2017 after selling out during the quarter.
  • V Wealth Advisors sold 100 Trillium Therapeutics Inc. shares in Q3 2017.
  • V Wealth Advisors first reported a position in Trillium Therapeutics Inc. in Q2 2017 and held it in 1 quarter.
  • V Wealth Advisors's Trillium Therapeutics Inc. position peaked at $0 in Q2 2017.
  • 20 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2017.

Based on V Wealth Advisors's 13F filing for Q3 2017, filed 12 Oct 2017.